secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2022-04-25T23:59:59+00:00
Accession:  0001193125-22-116353
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta reports 60% CR for NKX101 in AML; 83% ORR for NKX019 in NHL
------------------------------------------------------------------

- NKX101: 3/5 AML patients at 1B/1.5B cells x3 achieved CR (60%); 2 of 3 CRs are MRD negative.
- NKX019: 5/6 NHL patients at 1B cells x3 achieved response (83% ORR); 3/6 CR (50% CR).
- No CRS, neurotoxicity, or GvHD reported for either program; safety profile favorable.
- Both programs advancing to 1.5B cells x3 dose regimen for recommended Phase 2 dose.
- Phase 1 trials continue enrolling; updated data to be submitted to future medical meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000119312522116353/0001193125-22-116353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000119312522116353/d219241d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-116353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer